About - ELUT :

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Employees - 54, CEO - Dr. C. Randal Mills Ph.D., Sector - Healthcare, Country - US, Market Cap - 229.36M

Altman ZScore(max is 10): -9.47, Piotroski Score(max is 10): 3, Working Capital: $-2360000, Total Assets: $48407000, Retained Earnings: $-220532000, EBIT: -68587000, Total Liabilities: $88645000, Revenue: $24782000

- Current Price $4.84 - Analyst Target Price $9.00

Stats & Key Metrics
TickerELUT
Index-
Curent Price 4.84
Change37.11%
Market Cap229.36M
Average Volume37.02K
Income-60.42M
Sales24.78M
Book Value/Share-1.16
Cash/Share0.54
Dividend Est-
Dividend TTM-
Dividend Ex-Date-
Employees54
Moving Avg 20days14.91%
Moving Avg 50days25.28%
Moving Avg 200days33.22%
Shares Outstanding30.25M
Earnings DateNov 14 AMC
Inst. Ownership32.57%
Key Ratios & Margins
Price/Earnings-
Forwad P/E-
PE Growth-
Price/Sales9.26
Price/Book-
Price/Cash8.91
Price/FCF-
Quick Ratio0.85
Current Ratio0.94
Debt/Equity-
Return on Assets-117.51%
Return on Equity-
Return on Investment-
Gross Margin42.40%
Ops Margin-97.89%
Profit Margin-243.82%
RSI61.53
BETA(β)0.81
From 52week Low160.22%
From 52week High-7.63%
Earnings & Valuation
EPS-2.88
EPS next Year-0.91
EPS next Qtr-0.24
EPS this Year20.04%
EPS next 5 Year-
EPS past 5 Year-17.26%
Sales past 5 Year-5.10%
EPS Y/Y-19.76%
Sales Y/Y-41.19%
EPS Q/Q42.23%
Sales Q/Q-3.35%
Sales Surprise-10.27%
EPS Surprise-56.25%
ATR(14)0.44
Perf Week16.91%
Perf Month10.50%
Perf Quarter25.71%
Perf Year144.44%
Perf YTD124.07%
Target Price9.00

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer